Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

Radiofrequency ablation (RFA)is an advanced, minimally invasive technique in the treatment of patients with lung cancer and has been found to be both safe and technically feasible with a high local efficacy, but for he size of the lesion is over 3.0 cm diameter there is less effective. Iodine-131-labeled nuclei of tumor cells chimeric monoclonal antibody, a novel radioimmunotherapy provided a new therapeutic approaches for lung cancer, but the complete response is low. For RFA can induce a mass complete tumor necrosis which greatly increase the targeting area for radioimmunotherapy, thus RFA followed by ¹³¹I-nuclei of tumor cells chimeric monoclonal antibody adjuvant treatment may apparently improve the therapeutic efficacy of lung cancer, especially for tumors larger than 3.0 cm diameter.